Key points from article :
PCSK9 inhibitors are an effective therapy for lowering LDL cholesterol.
Combination of evolocumab and statins significantly reduced risk of cardiovascular events.
Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin 9.
PCSK9 protein reduces the liver’s ability to remove LDL cholesterol from the blood.
Patients with under 10 mg/dL LDL cholesterol had 40 % lower risk of CV events.
The study was published in The Lancet medical journal.
